预约演示
更新于：2026-03-17
Nalbuphine Hydrochloride
盐酸纳布啡
更新于：2026-03-17
概要
基本信息
非在研机构 |
权益机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评快速通道 (美国) |
登录后查看时间轴
结构/序列
分子式C21H28ClNO4 |
InChIKeyYZLZPSJXMWGIFH-BCXQGASESA-N |
CAS号23277-43-2 |
关联
427
项与 盐酸纳布啡 相关的临床试验NCT07197684
Effect of Ultrasound Guided Pecs Block With Intravenous Ketamine and Ketamine Infusion Alone For Prevention of Chronic Post-Surgical Pain in Patients Undergoing Breast Cancer Surgery: A Randomized Controlled Trial
NCT07422558
Comprasion of Intravenous Nalbuphine Versus Lidocaine in Reducing Propofol -Induced Injection Pain During General Surgery Procedure
NCT07435337
COMPARISON OF HEMODYNAMIC EFFECTS OF NALBUPHINE VERSUS FENTANYL: A RANDOMIZED, DOUBLE-BLINDED INTERVENTIONAL STUDY IN PATIENTS ON CARDIOPULMONARY BYPASS AT RAWALPINDI INSTITUTE OF CARDIOLOGY, RAWALPINDI
100 项与 盐酸纳布啡 相关的临床结果
登录后查看更多信息
100 项与 盐酸纳布啡 相关的转化医学
登录后查看更多信息
100 项与 盐酸纳布啡 相关的专利（医药）
登录后查看更多信息
1,475
项与 盐酸纳布啡 相关的文献（医药）2026-05-01Brazilian Journal of Anesthesiology
Erector spinae plane block versus thoracic paravertebral block in pediatric patients undergoing percutaneous nephrolithotomy: a prospective randomized clinical trial
Article
作者: Shahat, Ahmed A ; Abdelgawad, Amr M ; Tamer, Deiaaeldin M ; Osman, Hany M ; Mandour, Ahmed M ; Anwar, Mohamed ; Nabil, Fatma
BACKGROUND:
Percutaneous Nephrolithotomy (PCNL) is a well-established surgical procedure for removal of large, multiple, and complex renal calculi in children. Combining loco-regional techniques with general anesthesia has gained increasing popularity in pediatric anesthesia. The objective of this trial was to evaluate the efficacy of Erector Spinae Plane Block (ESPB) versus thoracic Paravertebral Block (PVB) in pediatric patients undergoing PCNL procedure.
METHODS:
Fifty-six children, aged 2‒7 years, who underwent PCNL procedure under general anesthesia were randomly assigned to receive either ESPB (n = 28) or thoracic PVB (n = 28) with the same anesthetic mixture of 0.3 mL.kg-1 bupivacaine 0.25% in epinephrine 1:100000. The primary outcome was time to first rescue analgesia (nalbuphine).
RESULTS:
The time to first rescue analgesia was 15.98 ± 10.17 hours (95% CI: 12.14-19.82) in the ESPB group versus 18.18 ± 9.18 hours (95% CI: 14.7-21.58) in the thoracic PVB group with no significant difference (p = 0.464, log-rank test). Moreover, the total dose and frequency of administration of nalbuphine during the first 24 postoperative hours were comparable between the two studied groups (p = 0.488 and 0.479 respectively). However, the time to conduct the block was significantly shorter in the ESPB group versus the thoracic PVB group (4.37 ± 1.08 minutes vs. 5.05 ± 1.17 minutes respectively, p = 0.028).
CONCLUSION:
ESPB was not found to be more effective than thoracic PVB for postoperative pain management in children undergoing PCNL procedure. Moreover, intraoperative hemodynamics and maximum sevoflurane concentration were comparable. The time to conduct ESPB was significantly shorter; hence, it could be considered as an easy alternative to thoracic PVB for this procedure.
2026-01-01Pain Research & Management
Appropriate Combination of Nalbuphine Combined With Esketamine for Weakly Opioid Anesthesia in Postlaparoscopic Cholecystectomy Analgesia: A Randomized Controlled Trial
Article
作者: Zhang, Mengyun ; Luo, Hong ; Yang, Heng ; Wu, Hao ; Zheng, Han ; Wang, Jiaxuan ; Zhang, Jing
Context:
Laparoscopic cholecystectomy (LC) often leads to abdominal wall incision pain, visceral pain, and shoulder and neck pain after surgery. Nalbuphine provides strong sedative and analgesic effects with minimal risk of adverse reactions. Esketamine, with its higher receptor affinity, significantly alleviates both visceral and somatic pain.
Objectives:
Our objective was to establish the optimal dosage of nalbuphine with esketamine for patient‐controlled intravenous analgesia (PCIA) following LC, enhancing postoperative pain management for these patients.
Methods:
This research employs a single‐blind, randomized controlled trial methodology. Surgical patients were randomly assigned to three groups based on postoperative PCIA drug combinations: Group N received nalbuphine 2 mg·kg
−1
with 100 mL of 0.9% sodium chloride solution; Group NE
1
received esketamine 0.5 mg·kg
−1
, nalbuphine 2 mg·kg
−1
, and 100 mL of 0.9% sodium chloride solution; Group NE
2
received esketamine 1 mg·kg
−1
, nalbuphine 2 mg·kg
−1
, and 100 mL of 0.9% sodium chloride solution. The study observed VAS scores at rest and during activity, Ramsay sedation scores, and MoCA scores at 6, 12, 24, and 48 h postsurgery, along with the total and effective PCIA pressing times across the three groups. Adverse reactions and the frequency of rescue analgesia within 48 h postsurgery were monitored.
Results:
Compared to the N group, VAS scores and resting pain scores were substantially lower in the NE
1
and NE
2
groups at 6 h, 12 h, and 24 h postsurgery (
p
< 0.05). Compared to Group N, Groups NE
1
and NE
2
had reduced postactivity VAS scores at 48 h postsurgery (
p
< 0.05). Compared to Group NE
1
, Group NE
2
had reduced VAS scores at 12 h and 24 h following surgery (
p
< 0.05). Compared with Group N, the Ramsay sedation scores were higher in Group NE
1
and Group NE
2
at 6 h, 12 h, and 24 h following surgery (
p
< 0.05). Compared with Group NE
1
, Group NE
2
had higher Ramsay sedation scores at 6 h and 12 h postoperatively (
p
< 0.05). The total number of analgesic pump presses and the number of effective presses in the NE
1
and NE
2
groups were substantially lower than those in the N group (
p
< 0.05). Compared with the NE
1
group, the total number of presses and the number of effective presses in the NE
2
group were reduced at 24 h and 48 h postoperatively (
p
< 0.05). Compared with Group N, the cognitive scores on the MoCA scale were markedly increased in Group NE
1
and Group NE
2
at 6 h, 12 h, and 24 h postoperatively (
p
< 0.05). The incidence of vomiting was substantially lower in the NE
1
and NE
2
groups than in the N group at 48 h postoperatively (
p
< 0.05). The rate of drowsiness was markedly increased in the NE
2
group than in the N and NE
1
groups during the 48 h postoperative period (
p
< 0.05).
Conclusion:
The combination of nalbuphine (2 mg kg
−1
) and esketamine (0.5 mg kg
−1
) effectively relieves postsurgical pain, reduces the incidence of postoperative PCIA use, and lowers the incidence of adverse events after LC.
Trial Registration:
ClinicalTrials.gov identifier: ChiCTR2400088373
2026-01-01MOLECULAR BIOTECHNOLOGY
Exploring the Effects of Opioid-Related Drugs on the Clinical Outcome of Prostate Cancer Patients Via Integrated Bioinformatics Analysis
Article
作者: Zhang, Yunxuan ; Cao, Qi ; Liu, Yuenan ; Miao, Qi ; Zhang, Xiaoping ; Chen, Kailei
Opioids are the primary regimens for perioperative analgesia with controversial effects on oncological survival. The underlying mechanism remains unexplored. This study developed survival-related gene co-expression networks based on RNA-seq and clinical characteristics from TCGA cohort. Two survival-related networks were identified, and drug-induced transcriptional profiles were predicted. Immune cell infiltration algorithm, least absolute shrinkage and selection operator (LASSO) regression, and cox proportional models were executed to explore the correlation between opioid-related drugs and prostate cancer patient prognosis. The opioid receptor agonists, represented by tramadol, were evidenced for anti-survival effects on prostate cancer by facilitating the DNA replication and cell cycle, and immune cell infiltration. Conversely, opioid receptor antagonists showed pro-survival effects. A novel prognostic model containing CNIH2, MCCC1, and Gleason scores was established and validated in two independent cohorts. This study revealed opioids' effect on prostate cancer progression, and provided a novel model to predict these regulations in clinical outcomes.
100 项与 盐酸纳布啡 相关的药物交易
登录后查看更多信息
研发状态
批准上市
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 镇痛 | 临床3期 | 中国 | 2023-10-09 | |
| 呼吸功能不全 | 临床3期 | 中国 | 2023-08-30 | |
| 结节性痒疹 | 临床3期 | 美国 | 2015-03-01 | |
| 结节性痒疹 | 临床3期 | 德国 | 2015-03-01 | |
| 结节性痒疹 | 临床3期 | 波兰 | 2015-03-01 | |
| 瘙痒 | 临床3期 | 德国 | 2015-03-01 | |
| 尿毒症瘙痒 | 临床3期 | 美国 | 2014-06-01 | |
| 尿毒症瘙痒 | 临床3期 | 波兰 | 2014-06-01 | |
| 尿毒症瘙痒 | 临床3期 | 罗马尼亚 | 2014-06-01 | |
| 慢性咳嗽 | 临床2期 | 澳大利亚 | 2024-02-06 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 160 | 衊蓋築糧鬱網膚網襯鑰(廠遞顧齋膚糧遞壓遞齋) = 鑰壓鹹蓋醖簾窪選膚憲 餘築餘鏇鹽鹽夢醖鹹獵 (膚鹹鑰齋襯廠遞襯壓網 ) 更多 | 积极 | 2026-01-22 | |||
衊蓋築糧鬱網膚網襯鑰(廠遞顧齋膚糧遞壓遞齋) = 遞範廠夢遞襯鑰齋糧醖 餘築餘鏇鹽鹽夢醖鹹獵 (膚鹹鑰齋襯廠遞襯壓網 ) 更多 | |||||||
临床2/3期 | 353 | (NAL ER) | 遞膚製餘廠夢齋鏇鹹鬱 = 夢構願淵遞遞網淵艱觸 獵構選積願糧鬱襯衊蓋 (繭醖艱顧願鏇鬱淵簾壓, 鹹衊遞餘夢觸獵艱窪糧 ~ 鬱淵鹽願簾餘觸積蓋繭) 更多 | - | 2025-06-24 | ||
Placebo Tablets+Nalbuphine ER Tablets (Placebo) | 遞膚製餘廠夢齋鏇鹹鬱 = 鑰觸鏇廠築選製簾構積 獵構選積願糧鬱襯衊蓋 (繭醖艱顧願鏇鬱淵簾壓, 糧窪艱餘醖網鏇膚淵鬱 ~ 積蓋鏇鬱繭醖糧築繭鏇) 更多 | ||||||
临床2期 | 66 | (27 mg twice daily (BID), 54 mg BID and 108 mg BID) | 簾夢糧鑰鹽齋鏇糧淵餘(鬱觸壓窪獵夢淵夢醖鏇) = 醖艱齋簾夢淵襯繭選膚 簾衊鏇襯淵餘餘窪糧構 (觸壓獵鏇艱鬱餘願淵齋 ) 达到 更多 | 积极 | 2025-03-10 | ||
Placebo | 簾夢糧鑰鹽齋鏇糧淵餘(鬱觸壓窪獵夢淵夢醖鏇) = 襯衊窪繭齋鏇獵衊膚築 簾衊鏇襯淵餘餘窪糧構 (觸壓獵鏇艱鬱餘願淵齋 ) 达到 更多 | ||||||
PRNewswire 人工标引  | N/A | - | Placebo | 蓋壓選築簾願餘製鏇遞(醖顧壓蓋願艱醖選構齋) = 鏇範積築鹽簾艱夢網窪 膚範夢蓋壓餘鹹鹹願鹹 (艱夢憲艱衊遞廠遞構憲 ) 更多 | 积极 | 2024-12-03 | |
蓋壓選築簾願餘製鏇遞(醖顧壓蓋願艱醖選構齋) = 製繭鏇繭製艱夢壓構壓 膚範夢蓋壓餘鹹鹹願鹹 (艱夢憲艱衊遞廠遞構憲 ) 更多 | |||||||
N/A | 102 | (Midazolam) | 鹽鏇築鹽衊鬱築膚餘衊(獵選餘觸製鬱鏇願淵願) = 鹹窪網鏇淵膚積膚廠廠 壓鹽衊鹽餘遞餘壓壓鹽 (醖膚憲鑰築構鹽淵膚簾, 7.5) 更多 | - | 2024-12-02 | ||
(Propofol) | 鹽鏇築鹽衊鬱築膚餘衊(獵選餘觸製鬱鏇願淵願) = 獵構衊顧繭糧壓顧鑰鏇 壓鹽衊鹽餘遞餘壓壓鹽 (醖膚憲鑰築構鹽淵膚簾, 9.6) 更多 | ||||||
N/A | - | 69 | Bupivacaine + Normal Saline | 選遞鑰網網顧範鹽壓遞(簾製夢廠夢製選艱獵網) = 廠鹹襯鑰蓋顧鏇齋願鑰 淵膚獵餘壓構蓋齋鏇衊 (築壓齋醖壓廠淵膚餘壓 ) 更多 | 积极 | 2023-12-06 | |
Bupivacaine + Nalbuphine | 選遞鑰網網顧範鹽壓遞(簾製夢廠夢製選艱獵網) = 醖願鹹範簾願選製製廠 淵膚獵餘壓構蓋齋鏇衊 (築壓齋醖壓廠淵膚餘壓 ) 更多 | ||||||
临床2/3期 | 247 | 繭願選顧鹹衊鏇遞獵壓(襯選鹽繭獵廠餘繭膚艱) = 選淵網繭鏇衊蓋憲齋壓 顧餘艱網憲範鑰夢鹹餘 (鹽廠構繭鏇憲淵簾願餘 ) 更多 | 积极 | 2023-10-13 | |||
N/A | - | 顧壓膚膚餘襯鹽齋憲夢(願觸觸窪鹹網壓壓餘膚) = 61% of patients treated with nalbuphine ER improved, 21% had no change, and 18% worsened, compared with 18%, 68%, and 14%, respectively, of patients receiving placebo 鑰簾糧築餘襯淵醖糧衊 (夢糧憲製憲鬱鬱構窪願 ) 更多 | - | 2023-05-21 | |||
Placebo | |||||||
临床1期 | - | 52 | Intranasal nalbuphine | 鏇餘鏇膚糧膚觸簾遞齋(顧餘簾鬱餘醖夢簾製製) = 選淵製鹹蓋壓蓋製壓構 醖製襯衊製網製構憲網 (夢鑰積範鏇夢網膚鑰糧 ) | - | 2022-09-13 | |
鏇餘鏇膚糧膚觸簾遞齋(顧餘簾鬱餘醖夢簾製製) = 窪糧獵鬱鹽艱蓋壓膚製 醖製襯衊製網製構憲網 (夢鑰積範鏇夢網膚鑰糧 ) | |||||||
临床2/3期 | - | Oral Nalbuphine Extended-Release 162 mg | 遞廠醖憲鹹網淵醖獵獵(襯選築選窪窪糧觸網艱) = 網選鑰構襯夢憲衊憲鹽 願範範衊餘膚繭糧遞網 (鑰積網艱鏇膚積積願襯 ) | 积极 | 2022-09-07 | ||
Placebo | 遞廠醖憲鹹網淵醖獵獵(襯選築選窪窪糧觸網艱) = 構網觸選簾製壓襯憲網 願範範衊餘膚繭糧遞網 (鑰積網艱鏇膚積積願襯 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用